Abstract
Cholinergic deficit is a cardinal feature of Alzheimers disease, and cholinesterase inhibitors represent one of the most prominent means of mitigating this dysfunction. Cholinesterase inhibitors provide mild symptomatic relief, although they lose their efficacy over time most likely because they are not disease-modifying agents. An alternative strategy for restoring cholinergic function and attenuating the cognitive decline involves acting on the receptors on which acetylcholine acts. Stimulation of muscarinic acetylcholine receptors and in particular the M1 subtype has been shown to have a beneficial effect in restoring cognition in patients with Alzheimers disease and in attenuating Aβ and tau pathology in different animal models. In this review, we discuss the role of M1 agonists as a potential disease – modifying therapy for Alzheimers disease.
Keywords: M1 Agonists, Alzheimer's disease, cholinesterase inhibitors, acetylcholine receptors, cholinergic neurons
Current Alzheimer Research
Title: M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease
Volume: 6 Issue: 2
Author(s): Antonella Caccamo, Abraham Fisher and Frank M. LaFerla
Affiliation:
Keywords: M1 Agonists, Alzheimer's disease, cholinesterase inhibitors, acetylcholine receptors, cholinergic neurons
Abstract: Cholinergic deficit is a cardinal feature of Alzheimers disease, and cholinesterase inhibitors represent one of the most prominent means of mitigating this dysfunction. Cholinesterase inhibitors provide mild symptomatic relief, although they lose their efficacy over time most likely because they are not disease-modifying agents. An alternative strategy for restoring cholinergic function and attenuating the cognitive decline involves acting on the receptors on which acetylcholine acts. Stimulation of muscarinic acetylcholine receptors and in particular the M1 subtype has been shown to have a beneficial effect in restoring cognition in patients with Alzheimers disease and in attenuating Aβ and tau pathology in different animal models. In this review, we discuss the role of M1 agonists as a potential disease – modifying therapy for Alzheimers disease.
Export Options
About this article
Cite this article as:
Caccamo Antonella, Fisher Abraham and LaFerla M. Frank, M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease, Current Alzheimer Research 2009; 6 (2) . https://dx.doi.org/10.2174/156720509787602915
DOI https://dx.doi.org/10.2174/156720509787602915 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology
Current Pharmaceutical Design N-alkylated Tacrine Derivatives as Potential Agents in Alzheimer’s Disease Therapy
Current Alzheimer Research Platelets and Vascular Risk: An Option for Treatment
Current Pharmaceutical Design Pro-Inflammatory Cytokines IL-1β and TNF-α are not Associated with Plasma Homocysteine Concentration in Alzheimer’s Disease
Current Alzheimer Research Data Tagging in Medical Images: A Survey of the State-of-Art
Current Medical Imaging Patent Selections
Recent Patents on Drug Delivery & Formulation Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Psychological Stress in Pathogenesis of Essential Hypertension
Current Hypertension Reviews The Mitochondriotropic Effects of L-carnitine and its Esters in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Infrared-Spectroscopy: A Non-Invasive Tool for Medical Diagnostics and Drug Analysis
Current Medicinal Chemistry Neurodegenerative Disorders and Cholesterol
Current Alzheimer Research Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease
Current Topics in Medicinal Chemistry Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design Integration of Cognitive Tests and Resting State fMRI for the Individual Identification of Mild Cognitive Impairment
Current Alzheimer Research Cholesterol in Alzheimers Disease: Unresolved Questions
Current Alzheimer Research Utility of Recombinant Cytochrome P450 Enzymes: A Drug Metabolism Perspective
Current Drug Metabolism Modulating Mesenchymal Stromal Cell Function with Cholesterol Synthesis Inhibitors
Current Medicinal Chemistry Meet Our Section Editor:
Current Pharmaceutical Biotechnology Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design